Altimmune, Inc. announced an underwritten public offering of its common stock and warrants to raise funds for its upcoming Phase 3 clinical trial of pemvidutide, a drug targeting serious liver diseases including metabolic dysfunction-associated steatohepatitis (MASH). The offering is subject to market conditions and aims to support the trial as well as general corporate purposes. Joint bookrunners for the offering are Leerink Partners and Barclays, with Titan Partners as co-bookrunner. This capital raise is crucial for advancing Altimmune’s lead candidate through late-stage development and potential regulatory milestones.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
